. intolerance). Ibrutinib is The existing gold common therapy for sufferers with relapsed/refractory condition, based upon the outcomes of several section I-III trials, one hundred fifteen–119 but This really is also shifting for two main factors: (i) an increasing proportion of sufferers at present receive ibrutinib as frontline therapy; and (ii